Ved afslutning af en fase III undersøgelse var i alt 90%, 95%, 98% og 60% af de personer, der modtog Silgard i en per- protokol immunogenicitet population, henholdsvis anti- HPV 6, anti- HPV 11, anti- HPV 16 og anti- HPV 18 seropositive.
In phase III studies, at end of study 90%, 95%, 98% and 60% of subjects who received Silgard in the per-protocol immunogenicity population were anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti HPV 18 seropositive, respectively.